The Impact of Maternal High-Fat Diet on Stem Cell Programming and Disease Susceptibility in Offspring.
Gao J., Tian Q., Li S., Zheng L., Zhou Y.
Narrative Review, published in Mol Nutr Food Res (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Mol Nutr Food Res (2025)
- Country
- Germany
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41158066
- DOI
- 10.1002/mnfr.70303
- Citations
- 1
Abstract (original English)
Stem cells are the fundamental origin of fetal life, and their proliferation and differentiation are pivotal for development, health, and disease susceptibility. Emerging evidence indicates that a maternal high-fat diet (MHFD) during pregnancy and lactation disrupts the intrauterine milieu, thereby impairing stem cell development. This review synthesizes current findings on maternal HFD effects on hematopoietic stem/progenitor cells (HSPCs), neural stem cells (NSCs), adipose-derived stem cells (ASCs), osteo-progenitors, and intestinal stem cells (ISCs) in offspring. Particular emphasis is placed on molecular pathways and metabolic pathways through which maternal HFD regulates stem cell fate. Perturbations in these mechanisms, mediated by epigenetic modifications and gut microbiota dysbiosis, elevate the risk of metabolic disorders, neurodevelopmental deficits, and inflammatory diseases in progeny. Furthermore, this review highlights potential therapeutic strategies, including dietary interventions, epigenetic modulators, and microbiota-targeted therapies, that may mitigate the adverse impact of maternal HFD on stem cell programming and long-term health.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.